Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)

ClinicalTrials.gov ID: NCT00325403

Public ClinicalTrials.gov record NCT00325403. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 3, 2026, 12:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 12-Week, International, Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison of the Efficacy and Safety of Oral UT-15C Sustained Release Tablets in Subjects With Pulmonary Arterial Hypertension

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study was an international, multicenter, randomized (2:1 active:placebo), double-blind, placebo-controlled study in subjects with PAH who were NOT currently receiving approved therapy for their PAH. Study visits occurred at 4 week intervals for 12 weeks (with an additional visit at Week 11) with the key measure of efficacy being the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. Two optional substudies were also a part of FREEDOM-M at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 12 and a genetics and biomarkers substudy with blood samples collected at Baseline and Week 12. Patients who completed all assessments for 12 weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).

Study identification

NCT ID
NCT00325403
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
United Therapeutics
Industry
Enrollment
349 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 30, 2006
Primary completion
Mar 31, 2011
Completion
Mar 31, 2011
Last update posted
Jan 2, 2024

2006 – 2011

United States locations

U.S. sites
43
U.S. states
27
U.S. cities
37
Facility City State ZIP Site status
University of Alabama-Birmingham Birmingham Alabama
Arizona Pulmonary Specialist Phoenix Arizona
Mayo Clinic Arizona Phoenix Arizona
University of California, San Francisco-Fresno Fresno California
West Los Angeles VA Healthcare Center Los Angeles California
UC Davis Medical Center Sacramento California
Harbor-UCLA Medical Center Torrance California
University of Colorado Health Science Center Aurora Colorado
University of Florida - Shands Hospital Jacksonville Florida
Cleveland Clinic Florida Weston Florida
Emory University Hospital Atlanta Georgia
University of Chicago Hospitals Chicago Illinois
University of Iowa Hospital and Clinics Iowa City Iowa
Kentuckiana Pulmonary Associates Louisville Kentucky
Alexandria Cardiology Clinic Alexandria Louisiana
Maine Medical Center Portland Maine
University of Maryland School of Medicine Baltimore Maryland
Brigham and Women's Hospital Boston Massachusetts
Tufts Medical Center Boston Massachusetts
University of Michigan Ann Arbor Michigan
Mayo Clinic Rochester Minnesota
Washington University Hospital St Louis Missouri
Nebraska Medical Center Omaha Nebraska
Newark Beth Israel Medical Center Newark New Jersey
Winthrop University Hospital Mineola New York
Columbia Presbyterian Medical Center New York New York
Mary M Parkes Center for Asthma, Allergy and Pulmonary Care - University of Rochester Rochester New York
The Lindner Center Cincinnati Ohio
University of Cincinnati Cincinnati Ohio
The Cleveland Clinic Foundation Cleveland Ohio
University Hospitals of Cleveland Cleveland Ohio
Ohio State University Columbus Ohio
Legacy Clinic Northwest Portland Oregon
Oregon Health and Science University Portland Oregon
Allegheny General Hospital Pittsburgh Pennsylvania
University of Pittsburgh Medical Center Pittsburgh Pennsylvania
Medical University of South Carolina Charleston South Carolina
University of Texas Southwestern Dallas Texas
Baylor College of Medicine, Pulmonary & Critical Care Houston Texas
University of Texas Health Science Center at San Antonio San Antonio Texas
Inova Fairfax Hospital Falls Church Virginia
University of Washington Medical Center Seattle Washington
Heart Care Associates Milwaukee Wisconsin

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 34 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00325403, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 2, 2024 · Synced Sep 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00325403 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →